Test in Focus
In this episode of “A Test in Focus,” Sanjeev Sethi, M.D., Ph.D., explains Mayo Clinic Laboratories’ new immunohistochemistry assay for the detection of NELL-1 antigen, a biomarker for membranous nephropathy (MN). Identified by Dr. Sethi in 2019, NELL-1 antigen triggers the production of NELL-1 antibodies, which are present in approximately 10% to 15% of MN patients and may be associated with an underlying cancer.
“While many cases of NELL-1 are primary and there’s no disease association, there are multiple studies now that show a subset of NELL-1 positive patients have an underlying malignancy,” Dr. Sethi says. “So if a physician gets a diagnosis of NELL-1 membranous nephropathy, they need to be extra vigilant in screening for hidden malignancies, because it is possible that you treat the malignancy and then the membranous goes away as well.”
Dr. Sethi notes that establishing disease etiology through NELL-1 antigen detection not only enables accurate diagnosis, but elevates treatment outcomes by providing a disease expression on which to base follow-up care.
Listen to learn more about how NELL-1 antigen testing enhances MN diagnosis by equipping providers with specific information on disease manifestation.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
NELL1 | Neural Epidermal Growth Factor-Like 1 Protein Immunostain, Technical Component Only (coming soon)
Identification of neural epidermal growth factor-like 1 protein (NELL1) primary membranous nephropathy
Cherisse Marcou, Ph.D., and Marissa Ellingson, M.S., CGC, discuss whole exome sequencing (WES) at Mayo Clinic Laboratories. The comprehensive evaluation uses next-generation sequencing to detect for single nucleotide variants, small insertions or deletions, and copy number variants on approximately 20,000 genes, enabling precision answers to accurately diagnose, manage, and treat patients with identified inherited illness.
Alicia Algeciras, Ph.D., describes Mayo Clinic Laboratories’ new blood test to detect NFLC, or neurofilament light chain protein. NFLC is a biomarker for several neurodegenerative conditions. The new assay can determine if a patient’s cognitive decline is due to a neurodegenerative condition or some other, reversible condition — while avoiding the need for more-invasive testing of cerebrospinal fluid.
Paul Jannetto, Ph.D., and Loralie Langman, Ph.D., discuss Mayo Clinic Laboratories' unique approach to urine drug testing for addiction rehabilitation. Designed to guide and monitor therapy, the comprehensive profile tests for the most commonly used substances, including alcohol and nicotine, for a complete picture of a patient’s substance use.